Dermata Therapeutics (DRMA)
(Delayed Data from NSDQ)
$4.20 USD
-1.00 (-19.23%)
Updated May 17, 2024 04:00 PM ET
After-Market: $4.30 +0.10 (2.38%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
DRMA 4.20 -1.00(-19.23%)
Will DRMA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for DRMA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DRMA
Dermata (DRMA) Up on FDA Nod to Begin Pivotal Study of Acne Drug
Dermata (DRMA) Gains on Positive FDA Response for Acne Candidate
DRMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for DRMA
Dermata Therapeutics GAAP EPS of -$0.47 beats by $5.83
Dermata Therapeutics announces exercise of warrants for $2.66M
Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
Dermata Therapeutics reports Q1 EPS (47c) vs. ($2.27) last year
DRMA Stock Earnings: Dermata Therapeutics Misses EPS for Q1 2024